Disease · MONDO_0005178
Comparisons in its trials73
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 73
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With Clinically Significant Upper and/or Lower Gastrointestinal Events (CSULGIEs) | 20 of 2,238 | 81 of 2,246 | 4,484 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With Moderate to Severe Abdominal Symptoms | 132 of 2,238 | 162 of 2,246 | 4,484 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With SUs | 5 of 2,238 | 11 of 2,246 | 4,484 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With CSULGIES or Symptomatic Ulcers (SUs) | 25 of 2,238 | 92 of 2,246 | 4,484 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects Withdrawn Due to GI Adverse Events (AEs) | 114 of 2,238 | 167 of 2,246 | 4,484 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: serious adverse events | 61 of 2,223 | 61 of 2,237 | 4,460 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects With a Clinically Significant Decrease From Baseline in Hematocrit and/or Hemoglobin | 45 of 2,184 | 123 of 2,167 | 4,351 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects Hospitalized in Last 6 Months at the Post Trial Interview | 82 of 2,047 | 79 of 2,048 | 4,095 | NCT00141102 | Trial comparisons |
| Celecoxib vs Oral Diclofenac Plus Omeprazole: Number of Subjects Alive at the Post Trial Interview | 2,018 of 2,047 | 2,023 of 2,048 | 4,095 | NCT00141102 | Trial comparisons |
| Active Arm vs Placebo Arm: serious adverse events | 100 of 585 | 88 of 584 | 1,169 | NCT00486434 | Trial comparisons |
| Tapentadol (CG5503) vs Oxycodone: Number of Participants With Treatment-emergent Adverse Events (TEAE) | 766 of 894 | 202 of 223 | 1,117 | NCT00361504 | Trial comparisons |
| Tapentadol (CG5503) vs Oxycodone: serious adverse events | 49 of 894 | 9 of 223 | 1,117 | NCT00361504 | Trial comparisons |
| Duloxetine vs Placebo: serious adverse events | 5 of 264 | 3 of 260 | 524 | NCT01018680 | Trial comparisons |
| 0.07 mg Lorecivivint vs Vehicle: deaths from any cause | 1 of 249 | 0 of 252 | 501 | NCT03928184 | Trial comparisons |
| 0.07 mg Lorecivivint vs Vehicle: serious adverse events | 12 of 249 | 13 of 252 | 501 | NCT03928184 | Trial comparisons |
| Lorecivivint vs Vehicle: deaths from any cause | 0 of 241 | 1 of 251 | 492 | NCT04385303 | Trial comparisons |
| Lorecivivint vs Vehicle: serious adverse events | 4 of 241 | 1 of 251 | 492 | NCT04385303 | Trial comparisons |
| CR845 Tablet vs Placebo Tablet: deaths from any cause | 0 of 316 | 0 of 160 | 476 | NCT02944448 | Trial comparisons |
| CR845 Tablet vs Placebo Tablet: serious adverse events | 9 of 316 | 1 of 160 | 476 | NCT02944448 | Trial comparisons |
| DLX30-PLA vs PLA-DLX60: serious adverse events | 3 of 207 | 2 of 217 | 424 | NCT00945945 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005178/comparisons